Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production by Tobío Ageitos, Araceli et al.
Oncogenic D816V-KIT signaling in mast cells causes 
persistent IL-6 production
by Araceli Tobío, Geethani Bandara, Denise A. Morris, Do-Kyun Kim, Michael P. O'Connell,
Hirsh D. Komarow, Melody C. Carter, Daniel Smrz, Dean D. Metcalfe, and Ana Olivera 
Haematologica 2019 [Epub ahead of print]
Citation: Araceli Tobío, Geethani Bandara, Denise A. Morris, Do-Kyun Kim, Michael P. O'Connell,
Hirsh D. Komarow, Melody C. Carter, Daniel Smrz, Dean D. Metcalfe, and Ana Olivera. 




E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2019 Ferrata Storti Foundation.
Published Ahead of Print on April 4, 2019, as doi:10.3324/haematol.2018.212126.
 Tobío et al., 1
 




Araceli Tobío1, Geethani Bandara1, Denise A. Morris1, Do-Kyun Kim1, Michael P. 
O’Connell2, Hirsh D. Komarow1, Melody C. Carter1, Daniel Smrz1, Dean D. Metcalfe1 ¶, Ana 
Olivera1¶* 
 
1Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA 
 
2Genetics and Pathogenesis of Allergy Section, Laboratory of Allergic Diseases, National 

















Main text: 4,294 
Number of Figures: 6 
 
Contains a Supplementary Appendix file: Supplementary Methods, Supplementary Tables 1 





We thank Robin Eisch in her role as protocol study coordinator, Linda Scott, the nurse 
practitioner on the study protocols, Pahul Hanjra and Irina Maric for providing information 
on patients and Daly Cantave for arranging for patient bone marrow samples.  
  
 Tobío et al., 2
Abstract 
 
Persistent dysregulation of IL-6 production and signaling have been implicated in the 
pathology of various cancers. In systemic mastocytosis, increased serum levels of IL-6 
associate with disease severity and progression, although the mechanisms involved are not 
well understood. Since systemic mastocytosis often associates with the presence in 
hematopoietic cells of a somatic gain-of-function variant in KIT, D816V-KIT, we examined 
its potential role in IL-6 upregulation. Bone marrow mononuclear cultures from patients with 
greater D816V allelic burden released increased amounts of IL-6 which correlated with the 
percentage of mast cells in the cultures. Intracellular IL-6 staining by flow cytometry and 
immunofluorescence was primarily associated with mast cells and suggested a higher 
percentage of IL-6 positive mast cells in patients with higher D816V allelic burden. 
Furthermore, mast cell lines expressing D816V-KIT, but not those expressing normal KIT or 
other KIT variants, produced constitutively high IL-6 amounts at the message and protein 
levels. We further demonstrate that aberrant KIT activity and signaling are critical for the 
induction of IL-6 and involve STAT5 and PI3K pathways but not STAT3 or STAT4. 
Activation of STAT5A and STATB downstream of D816V-KIT was mediated by JAK2 but 
also by MEK/ERK1/2, which not only promoted STAT5 phosphorylation but also its long-
term transcription. Our study thus supports a role for mast cells and D816V-KIT activity in 
IL-6 dysregulation in mastocytosis and provides insights into the intracellular mechanisms. 
The findings contribute to a better understanding of the physiopathology of mastocytosis and 
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Introduction 
 
Mastocytosis defines a group of heterogeneous disorders characterized by the accumulation 
of neoplastic/clonal mast cells in the skin, bone marrow (BM) and other organs 1. 
Mastocytosis is clinically subdivided into systemic (SM) and cutaneous (CM) mastocytosis, 
both of which are comprised of several variants defined in accordance with histologic and 
clinical parameters and organ involvement 1. Somatic variants in the receptor for stem cell 
factor (SCF), KIT, that render it constitutively active often associate with SM, particularly 
p.(D816V), a missense in the tyrosine kinase domain of KIT. D816V-KIT may be 
accompanied by variants in other genes that further contribute to the oncogenic expansion of 
mast cells 2-4.  
 
Interleukin-6 (IL-6) is a pleiotropic cytokine produced by several cell types including 
stromal, hematopoietic and tumor cells. In addition to its involvement in normal 
inflammatory processes and host immune defense mechanisms, IL-6 may contribute to 
malignancy in a range of cancers including multiple myeloma, B cell and non-B cell 
leukemias and lymphomas 5, 6, by modulating cellular development, growth, apoptosis, 
metastasis and/or cellular resistance to chemotherapy 6. As elevated IL-6 levels in the serum 
of patients with such malignancies have been associated with poor clinical outcomes, 
blocking IL-6 or its synthesis in these patients is viewed as a potential therapeutic avenue 7, 8.   
 
In SM, the levels of serum IL-6 are higher in patients with aggressive versus indolent 
variants of SM and have been associated with adverse clinical features of mastocytosis such 
as accumulation of mast cells in the BM, organomegaly, elevated tryptase levels 9, 10, 
osteoporosis and/or bone pain 11. Although progression into more aggressive disease within 
patients with indolent SM (ISM) occurs only in a subset of patients, IL-6 plasma levels 
significantly correlate with disease progression and lower progression-free survival, 
suggesting that blockade of IL-6 synthesis or function may be beneficial in cases with 
aberrant IL-6 pathways 10. Other studies have shown that IL-6 promotes the differentiation, 
growth and degranulation of normal mast cells 12, and induces the production of reactive 
oxygen species by malignant mast cells and their accumulation in tissues in a model of 
mastocytosis 13. Despite the potential implications for disease pathology, the cell types and 
the mechanisms that may contribute to the constitutively elevated IL-6 levels in mastocytosis 
are not known. 
 
In this study, we test the hypothesis that cells expressing gain of function variants of KIT, 
particularly D816V-KIT, confer the ability to constitutively produce IL-6. As will be shown, 
ex-vivo BM mast cells from patients with SM release IL-6 in correlation with the allelic 
frequency of D816V-KIT. We further demonstrate that expression of D816V-KIT causes 
persistent IL-6 induction by mechanisms independent of autocrine feed-forward loops 
involving IL-6 and signal transducer and activator of transcription 3 (STAT3) described in 
other malignant cells, but dependent on oncogenic KIT-derived signals. These signals include 
phosphatidylinositide 3-kinase (PI3K) pathways and oncogenic STAT5 activation by both 
janus kinase 2 (JAK2) and, unexpectedly, by the mitogen-activated protein kinase 
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MEK/ERK1/2 pathways. These data expand our understanding of the potential mechanisms 
initiating enhanced IL-6 production in mastocytosis and emphasize targets for therapeutic 





A detailed description of the methods used in this study can be found in Online 
Supplementary Appendix  
 
Patients of study 
 
BM samples were obtained when clinically indicated from patients with SM classified 
according to the WHO guidelines 1, 3, 14 (Online Supplementary Table 1). All human samples 
were obtained after informed consent, on clinical protocols approved by the Institutional 
Review Board of the National Institute of Allergy and Infectious Diseases (02-I-0277 and 08-
I-0184) in agreement with the declaration of Helsinki. D816V-KIT mutation analysis and its 
allele burden in the BM (D816V-KIT frequency) were determined by allele-specific PCR 




Cell lines were cultured as described in the Online Supplementary Appendix. To obtain 
lysates for western blots, 3x106 cells were plated in 6 well plates and incubated with or 




Cells (3x106), were plated in 6 well plates for 2 h to overnight in 6 mL of serum-free media 
to exclude the possibility that any extrinsic stimulant present in the serum would influence 
the results. IL-6 released into the media was measured by ELISA (R&D Systems). Human 
colorectal carcinoma HCT116 cells were stimulated with 20 ng/mL µM PMA plus 1 µM 
ionomycin overnight and the supernatants then collected for IL-6 measurements.  
 
Mononuclear cells in BM aspirates from patients were cultured in StemPro-34 medium with 
human recombinant SCF (100 ng/mL) for 2 to 4 days. IL-6 released into the media was 
determined by ELISA. Alternatively, IL-6 expression in single cells was determined by flow 
cytometry using a LSRII flow cytometer. BM cells were incubated with Brefeldin A for 4 h 
and stained with an antibody cocktail containing anti-CD3-QDOT605, anti-CD34-APC, anti-
KIT-BV605 and anti-FcεRI-FITC, for 30 min. Cells were fixed, permeabilized and stained 
with anti-IL-6-PE for 30 min. Expression of IL-6 in mast cells (CD3-/CD34-/KIT+/FcεRI+) 
was analyzed using FlowJo software. 
 
Quantitative real-time PCR 
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HMC-1.2 cells (3x106) were plated in 6-well plates in 6 mL and incubated for 2 h in serum 
free media. Cellular RNA was extracted and reverse-transcribed into cDNA. cDNA was then 
amplified using TaqMan® Gene Expression Master Mix and Taqman® Gene Expression 
Assays for IL-6, STAT3, STAT4, STAT5A, STAT5B or GAPDH as described in the Online 
Supplementary Appendix.  
 
Knockdown of STAT transcription factors  
 
Knockdown of STAT3 and STAT4 was performed by lentiviral-mediated transduction of 
small hairpin RNA (sh-RNA) (Sigma-Aldrich, St. Louis, MO) as described 17. STAT5 
mRNA was silenced by a small interference-RNA (si-RNA) “ON-TARGET” pool from 




Data were expressed as mean ±SEM. Values were from at least 3 independent experiments, 
each performed at least in duplicate. Statistically significant differences were calculated by 
using the Student t-test (unpaired). Statistical significance was indicated as follows: *P 





Release of IL-6 from patient’s bone marrow cells and its association with D816V-KIT 
and mast cell frequencies 
 
The levels of IL-6 in serum 9 as well as the allelic frequency of D816V-KIT18 correlate 
with the levels of tryptase, a surrogate marker of mast cell burden. As mast cells often 
accumulate in the BM in SM, we tested the ability of BM cells to produce IL-6 in short-term 
cultures. BM mononuclear cells isolated from patients with SM showed varied ability to 
release IL-6 into the culture media after 2 to 4 days, with more release observed in cells from 
patients with a higher BM D816V-KIT allelic frequency (Figure 1A). Although cells other 
than mature mast cells may express D816V-KIT 18, the release of IL-6 into the media 
correlated with the percentage of mast cells within BM live cells (Figure 1B), suggesting a 
contributory role for mast cells in IL-6 production. Additionally, we analyzed intracellular 
IL-6 staining in single BM mast cells by flow cytometry from three separate patients 
described in the Online Supplementary Table 1. Patient 1 had idiopathic anaphylaxis and did 
not meet criteria for SM and thus was used as a control. This patient had no detectable 
D816V-KIT, 0.098% of BM cells were CD3-/CD34-/KIT+/FcεRI+ (mast cells) and a minor 
percentage of these were IL-6 positive (0.063%) (Figure 1C, left panel). However, CD3-
/CD34-/KIT+/FcεRI+ cells from patients 2 and 3, with BM D816V frequencies of 2.7% and 
5.5%, were ∼77% and 99% positive for IL-6, respectively (Figure 1C, middle and right 
panels). In this ex-vivo experiment, where BM cells were cultured up to 4 d in the presence of 
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SCF, cell lineages other than mast cells (KIT+/FcεRI-, KIT-/FcεRI+ and KIT-/FcεRI-) also 
showed positive intracellular IL-6 staining (Online Supplementary Table 2). However, the 
highest IL-6 mean fluorescence intensity (MFI) was associated with KIT+ cells. As SCF in 
the media may induce IL-6 directly or through autocrine/paracrine signals in clonal and non-
clonal cells in these cultures, we examined the expression of IL-6 in BM biopsies by 
immunofluorescence (IF). IF images of BM of patients with SM indicated that IL-6 
intracellular content was mostly associated with mast cells (Online Supplementary Figure 
S1). Thus, the combination of ex-vivo and in situ experiments suggests mast cells as the 
predominant producers of IL-6, with variable participation of other cell lineages. Data are 
also consistent with an association between increased IL-6 expression by BM mast cells and 
D816V-KIT frequency.  
  
Expression of D816V-KIT causes IL-6 upregulation and secretion 
 
Given these associations and that mast cells and their progenitors often carry somatic 
D816V-KIT variants in SM, we investigated the hypothesis that D816V-KIT expression 
intrinsically promotes IL-6 production. Thus, we analyzed the production of IL-6 at the 
protein and message levels in various cell lines expressing or not D816V-KIT. In agreement 
with our previous observations, the HMC-1.2 mastocytosis mast cell line which harbors KIT 
with D816V plus another missense variant in the juxta membrane domain of KIT (V560G), 
showed markedly higher IL-6 mRNA synthesis13 (Figure 2A, left panel) and IL-6 release 
than HMC-1.1 cells, which express only the monoallelic V560G-KIT variant (Figure 2A, 
right panel).  
 
The mastocytoma mouse mast cell line P815 carrying the homolog to the D816V-KIT variant 
(D814Y-KIT), also released significantly more IL-6 than primary mouse BMMCs (Figure 
2B). Furthermore, expression of human D816V-KIT in an immortalized mouse mast cell line 
that lacks KIT 13, 19, unlike cells expressing normal KIT or vector alone, released significant 
amounts of IL-6 into the media (Figure 2C). In aggregate, the results using the various mast 
cell lines demonstrate an association between expression of D816V-KIT in mast cells and 
persistent transcription and release of IL-6. This may not be restricted to mast cells, since 
introduction of D816V-KIT by CRISPR in the colorectal carcinoma cell line HCT116 also 
promoted IL-6 transcription and release (Figure 2D left and right panels, respectively) when 
cells were stimulated with PMA and ionomycin, indicating that in these cells D816V-KIT 
primes HCT116 cells for more robust IL-6 production.  
 
KIT tyrosine kinase activity is required for IL-6 production in mast cells 
 
Ligand-activated KIT signaling induces IL-6 production in mast cells and enhances IgE-
receptor-driven IL-6 production 20. Indeed, stimulation of KIT by SCF in the LAD2 cell line, 
which expresses normal KIT, induced IL-6 release, albeit the amounts were quantitatively 
limited (Figure 3A). HMC-1.1 showed higher production of IL-6 than LAD2 cells, 
particularly when stimulated with SCF (Figure 3A). However, not only was IL-6 production 
~100 fold higher in unstimulated HMC-1.2 than in LAD2 or HMC-1.1 cells, but ligand-
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induced stimulation of KIT did not cause any further IL-6 secretion by HMC-1.2 cells 
(Figure 3A). These data are consistent with the conclusion that ligand-independent signals 
induced by oncogenic KIT activity, particularly those from D816V-KIT, are more effective 
in inducing IL-6 secretion than ligand-activated KIT signals.   
 
We next blocked D816V-KIT activity in HMC-1.2 cells with dasatinib, a tyrosine kinase 
inhibitor that effectively suppresses the activity of the active, open conformation of D816V-
KIT. Dasatinib markedly reduced IL-6 mRNA levels (Figure 3B) and IL-6 secretion (Figure 
3C), while concentrations of the tyrosine kinase inhibitor imatinib that are ineffective in 
blocking D816V-KIT, did not alter IL-6 mRNA levels (Figure 3B), further suggesting an 
involvement of D816V-KIT signaling. Inhibition by gefitinib of the epidermal growth factor 
receptor (EGFR), a tyrosine kinase receptor that can drive IL-6 production in transformed 
cells 21, had no significant effects on IL-6 mRNA levels in HMC-1.2 cells (Figure 3B). 
Similar to HMC-1.2 cells, dasatinib effectively inhibited IL-6 release in P815 murine 
mastocytoma cells (Figure 3D). In contrast, persistent IL-6 production in HMC-1.2 cells did 
not appear to be mediated via feed-forward loops of activation by other receptors as those 
reported for the IL-6R 22, sphingosine-1-phosphate receptors 23 or the TGFβ receptor 24 in 
other neoplastic cells, since it was not altered by specific blockage of these receptors (Online 
Supplementary Figure S2 A-C). Overall, these data suggest that signals from D816V-KIT 
can promote ligand-independent IL-6 production without involving some of the most 
common autocrine feed-forward loops described in malignant cells.  
 
The constitutive release of IL-6 by unstimulated HMC-1.2 was enhanced by stimuli such as 
complement component 5a (C5a), IL-1 β, 10% FBS and PMA/ionomycin (Online 
Supplementary Figure S3A, left panel) suggesting that the production and secretion of IL-6 
due to D816V-KIT can synergize with other complementary signals or environmental cues.  
Of interest, the intracellular content of IL-6 protein was only ~10% of the total IL-6 released 
(Online Supplementary Figure S3A), and although dasatinib did not affect this percentage, it 
also reduced the total intracellular content. Thus, dasatinib inhibited the transcription, 
intracellular content and release of IL-6, (Figure 3B-C and Online Supplementary Figure 
S3A, right panel), consistent with the conclusion that D816V-KIT signals cause constitutive 
de novo production and release of IL-6 without regulating storage. In addition, we 
demonstrate that IL-6 protein released by HMC-1.2 cells is biologically active since 
conditioned media of these cells caused IL-6 receptor (IL-6R)-mediated STAT3 
phosphorylation in LAD2 cells which express and respond to IL-6R activation 12 (Online 
Supplementary Figure S3B). 
 
D816V-KIT-induced IL-6 production is dependent on JAK2, ERK and PI3K pathways 
 
MAPKs (ERK1/2 and p38) and PI3K pathways are part of the oncogenic signals derived 
from D816V-KIT activity 2, 25. Since these pathways may affect IL-6 expression 26-28, we 
investigated their potential roles in D816V-KIT-induced IL-6 production. While inhibition of 
p38 with SB203580 had minor effects on IL-6 synthesis, inhibition of the ERK1/2 pathway 
using a MEK1/2 inhibitor (U0126) (Figure 4A) or inhibition of the PI3K pathway by the 
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PI3Kα/δ/β inhibitor LY294002 (Figure 4B), caused a 50 to 60% reduction, respectively, in 
IL-6 production at the message (left panels) and protein levels (right panels).  
 
The JAK/STAT axis is also known to be prominently upregulated by D816V-KIT activity 29, 
30. JAK2 is activated by SCF 31 leading to STAT phosphorylation and translocation into the 
nucleus, where it exerts its transcriptional activity 32. Inhibition of JAK2 by the JAK2 
selective inhibitor fedratinib (TG101348) markedly blocked IL-6 constitutive transcription 
and cytokine release (Figure 4C, left and right panels, respectively). Ruxolitinib which 
inhibits JAK1 in addition to JAK2, similarly inhibited IL-6 expression, although at higher 
concentrations than fedratinib (Figure 4D). However, tofacitinib, a pan-JAK inhibitor 
preferential for JAK3 and to a lesser extent JAK1, was less effective (Figure 4D). Similar to 
HMC-1.2 cells, in mouse P815 cells inhibition of MEK/ERK1/2, PI3K or JAK2 pathways 
markedly reduced IL-6 release in mouse P815 cells (Figure 4E). The data thus implicate 
JAK2 in D816V-KIT induced IL-6 production.   
 
Since JAK2 activation has also been reported in certain cells to activate PI3K or ERK 32, 33, 
we further investigated the potential inter-relationships between JAK2 and the ERK and 
PI3K pathways. While inhibition of KIT by dasatinib, as expected, blocked the 
phosphorylation of JAK2, AKT and ERK1/2 signaling pathways downstream of the receptor 
by 40 to 80% (Figure 4F), inhibitors of JAK2, PI3K/AKT or MEK1/2/ERK1/2 reduced 
phosphorylation of their respective targets, but did not show significant effects on any of the 
others, suggesting that these signals are activated independently from each other. 
 
D816V-KIT-induced IL-6 production is dependent on STAT5 
 
JAK phosphorylates STATs, and STAT family members such as STAT3 34, 35, STAT4 36 and 
STAT5 37 have been implicated in the regulation of IL-6 transcription in various cells and 
conditions. As the levels of expression or phosphorylation of STAT3, STAT4 and STAT5 
(Online Supplementary Figures S4 A-C) are increased in HMC-1.2 and other cells with 
D816V-KIT 30; and STAT4 and STAT5 are upregulated in BM mast cells from patients with 
SM 29, 38, 39, we investigated their possible involvement in the induction of IL-6 transcription 
by silencing STAT3-5 expression using sh-RNA or si-RNA.    
 
Sh-RNA-mediated STAT3 silencing resulted in >75% reduction in STAT3 at the messenger 
and protein levels (Figure 5A) but did not affect IL-6 production by HMC-1.2 (Figure 5A, 
red bar). Similarly, a selective small inhibitor molecule for STAT3, C188-9, at 
concentrations that caused >80% reduction in STAT3 phosphorylation (Online 
Supplementary Figure S5A, upper panel) did not alter constitutive IL-6 production by these 
cells (Online Supplementary Figure S5A, lower panel). Neutralizing antibodies for the IL-
6R, which signals through STAT3, were also ineffective on IL-6 production (Online 
Supplementary Figure S2A). Reduction of STAT4 message and protein by >50% using sh-
RNA knockdown was also inconsequential for IL-6 persistent production by these cells 
(Figure 5B).   
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However, specific reduction in the mRNA for STAT5A or STAT5B messages by >50% and 
in protein expression (Figure 5C) using STAT5-specific si-RNA pools, resulted in 
concomitant reductions in IL-6 transcription (Figure 5D). Simultaneous knockdown of 
STAT5A and B did not accomplish significantly greater effects on IL-6 expression than 
silencing each individually (Figure 5 C-D), suggesting a redundant function for the two 
isoforms. The selective STAT5 inhibitor (CAS 285986-31-4), at a concentration that 
inhibited STAT5 phosphorylation by 50% (50 µM) (Online Supplementary Figure S5B, 
upper panel) also significantly reduced IL-6 transcription and IL-6 protein synthesis by 50% 
(Online Supplementary Figure S5B, lower panel, and C), a result that was also confirmed in 
P815 cells (Online Supplementary Figure S5D). As STAT5 is overexpressed and 
hyperactivated in cells carrying D816V (Online Supplementary Figure S4C) 29, 38, 39 and 
STAT5 mRNA was not depleted even when both STAT5A and B were silenced (Figure 5C), 
we treated STAT5-knockdown cells with the STAT5 inhibitor, which showed a reduction in 
IL-6 mRNA expression by 80% (Online Supplementary Figure S5E) consistent with the 
reduction observed by inhibition of JAK2. The results point towards JAK2/STAT5 as a 
major pathway leading to the constitutive expression of IL-6 in D816V-KIT expressing cells.  
 
ERK contributes to STAT5 phosphorylation and expression while the effect of the PI3K 
pathway on IL-6 is STAT5-independent 
 
As MAPKs have been implicated in the phosphorylation and the activation of STAT family 
members 40, we sought to determine whether ERK1/2 may contribute to the induction of IL-6 
by enhancing STAT5 phosphorylation. While inhibition of ERK1/2 did not affect JAK2 
phosphorylation (Figure 4F), it substantially inhibited STAT5 tyrosine phosphorylation 
(Figure 6A) and reduced STAT5 serine (Ser780) phosphorylation (Figure 6B), with the 
effects on STAT5 tyrosine phosphorylation being less pronounced than those of the JAK2 
and STAT5 inhibitors (Figure 6A). Simultaneous inhibition of both JAK2 and ERK1/2 
markedly blunted STAT5 phosphorylation (Figure 6B). In addition, inhibition of MEK/ERK 
also reduced STAT5A and STAT5B mRNA expression by 16 h, an effect that was not seen 
by 2 h (Figure 6C). The results implicate MEK/ERK1/2 as a dual regulator of STAT5 
activity (via JAK2-independent phosphorylation) and STAT5 transcription. In contrast, 
inhibition of PI3K had no effect on STAT5 phosphorylation or transcription in HMC-1.2 
cells (Figure 6 A, C), indicating the PI3K pathway regulates IL-6 independently of STAT5.   
 
Combination treatment of inhibitors for STAT5, ERK1/2 and PI3K markedly suppressed 
constitutive IL-6 expression (Figure 6D, left panel) and release (Figure 6D, right panel) in 
HMC-1.2 cells and in P815 cells (Figure 6E). Similarly, the JAK2 inhibitor fedratinib, 
currently in clinical trials, nearly ablated IL-6 production in HMC-1.2 cells when in 
combination with either (or both) PI3K and ERK1/2 inhibitors (Figure 6F), indicating the 
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IL-6 plays important roles in host defense, but if produced in an uncontrolled or persistent 
manner, it may be detrimental and contribute to the development of inflammatory diseases 
(e.g. rheumatoid arthritis and inflammatory bowel disease) and malignancies 7, 8, 41. Although 
little is known about the exact role of IL-6 in mastocytosis and how it is dysregulated, the 
levels of IL-6 in circulation correlate with mast cell burden and tissue involvement, 
osteoporosis 9, 11 and risk of progression 10. Our data suggest a contributory role for mast cells 
in IL-6 production in mastocytosis and implicate aberrant signaling of D816V-KIT as an 
initial event promoting persistent IL-6 transcription and consequent protein secretion. Among 
these aberrant signals, we identified increased JAK2 activity and MEK/ERK- and PI3K-
derived signals as drivers of IL-6 transcription, the former two by regulating the 
activation/expression of STAT5. The study provides the first clues into mechanisms leading 
to persistent IL-6 production in mastocytosis and potential target molecules for therapeutic 
intervention.  
 
Increased expression of IL-6 and its signaling through STAT3 in many malignancies can be 
driven by overexpression of IL-6Rs, coreceptors and regulators (such as JAK and STAT3), 
polymorphisms in the IL-6 promoter and/or oncogenic signaling from tyrosine kinase 
receptors such as EGFR/HER; and may occur when negative regulation is not fully effective 
34. Often, in malignant cells, production of IL-6 and constitutive STAT3 activation drive their 
own expression in feed-forward regulatory loops that are key for tumorigenesis 22, 23, 34, 41. 
Here, we show that upregulation of IL-6 in mast cells with the D816V-KIT missense variant 
does not involve the IL-6R and coreceptor gp130 (Supplemental Figure 2A) or feedback 
loops involving STAT3 (Figure 5). Moreover, STAT4, shown to enhance IL-6 transcription 
in human fibroblasts 36, had no role in IL-6 upregulation in HMC-1.2 mast cells. Instead, we 
demonstrate that persistent IL-6 production was dependent on oncogenic D816V-KIT 
activity and aberrant STAT5 activation, as it was suppressed by tyrosine kinase inhibitors 
that effectively block D816V-KIT tyrosine kinase activity and by STAT5 silencing or 
inhibition. In addition, BM mast cells from patients with mastocytosis produced and released 
IL-6 ex-vivo in correlation with D816V-KIT allelic burden (Figure 1). As STAT5 expression 
and phosphorylation are also upregulated in BM mast cells of patients with SM 29, 38, 39, our 
data suggest that oncogenic STAT5 activation may be a priming event contributing to the 
elevated serum IL-6 levels in mastocytosis. This does not exclude the involvement of other 
mechanisms such as IL-6-mediated feed-forward loops on other cell types in the surrounding 
tissue, which may drive IL-6 production further. In addition, it is important to note that, 
although most of the intracellular IL-6 staining was associated with mast cells in patient’s 
BM biopsies (Online Supplementary Figure S1), enhanced production of IL-6 in SM may not 
be restricted to mast cells as the presence of D816V-KIT may also induce or promote IL-6 
production in other clonal cells (Figure 2D and Online Supplementary Table 2). Furthermore, 
additional signals in the local environment could crosstalk with oncogenic KIT signals in 
mast cells or other hematopoietic clonal cells in SM with associated multilineage 
involvement, further contributing to IL-6 dysregulation.  
 
Even though canonical binding sites for STAT3 but not STAT5 are recognized in the IL-6 
promoter, stimulation of STAT5 by the IgE receptor in mast cells was reported to mediate 
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IL-6 production 37 and constitutively active STAT5 mutants to induce IL-6 expression 42. 
Whether active STAT5 in D816V-KIT mast cells binds directly to the IL-6 promoter driving 
transcription, or does so indirectly by binding other transcription factors 42 or by causing 
chromatin remodelling 43 needs further evaluation. Regardless, as STAT5 hyperactivation is 
critical for neoplastic D816V-KIT mast cell growth and survival 39, 44 and for normal mast 
cell development 45, our description of a novel regulatory role for STAT5 on constitutive IL-
6 expression supports targeting STAT5 for treatment of patients with mastocytosis and high 
IL-6 levels and potentially of patients with other hematological malignancies such as chronic 
myelogenous leukemia where serum IL-6 levels represent a predictor of outcome 46, 47 and 
pathogenesis is in part driven by constitutive STAT5 activation 48. 
The activation of STAT5 by D816V-KIT was complex and involved an interplay of JAK2- 
and MEK/ERK1/2-mediated pathways. JAK2-selective inhibitors such as fedratinib 
markedly reduced constitutive IL-6 production while the effectiveness of other pan-jakinibs 
correlated with their relative selectivity for JAK2, suggesting that JAK1 and 3 have no 
significant role. The specific involvement of JAK2 agrees with the notion that STAT5 is a 
major target for JAK2 in hematopoietic cells 29 and that activation of KIT by SCF causes 
JAK2 phosphorylation 31. Unlike for JAK2 inhibition, the effect of MEK/ERK1/2 inhibition 
on STAT5 activity and transcript abundance was unexpected. Phosphorylation in 
serine/threonine residues of STAT1/3/4 by MAPKs was reported to affect STAT1/3/4 
activity 33, 40. Although serine phosphorylation at the C-terminal tail of STAT5 proteins is 
essential for leukemogenesis 49 and for growth hormone induced gene expression 50, the 
serine/threonine kinases that mediate this type of phosphorylation or the exact functional 
implications and are not well understood. Surprisingly, in cells with D816V-KIT, inhibition 
of MEK/ERK1/2 caused a more pronounced effect on STAT5 phosphorylation at tyrosine 
694 (a target for JAK2) than at serine 780 (Figure 6) even though JAK2 activity was not 
affected by the ERK inhibitor (Figure 4). A similar JAK-independent role for ERK in STAT3 
tyrosine phosphorylation was reported in plasma cells for IL-6 27 but the mechanism for such 
regulation and what potential kinases or phosphatase may be involved need further 
evaluation.   
We also found a role for PI3K/AKT-dependent pathways on IL-6 induction in D816V-KIT 
mast cells but in a STAT5-independent manner, indicating that persistent IL-6 expression 
likely involves multiple transcription factors. Similar to STAT5 39, 44, oncogenic growth and 
survival of mast cells with D816V-KIT is also dependent on constitutive activation of AKT 2, 
30. Thus, combined targeting of STAT5 and PI3K/AKT pathways may be desirable to treat 
patients with mastocytosis and elevated IL-6, as was proposed for drug-resistant chronic 
myelogenous leukemia where both pathways are critical for disease evolution 44.  
Alternatively, since small molecule inhibitors for JAK2 such as fedratinib and the dual 
JAK1/2 inhibitor ruxolitinib inhibit STAT5 activity and IL-6 upregulation in neoplastic mast 
cells (Figure 4 and 6), and both drugs are approved by the US Federal Drug Administration 
for various blood disorders, they are also feasible drug candidates alone or in combination 
with other therapies for increased therapeutic index.  
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The work presented here links expression of the D816V-KIT variant with IL-6 persistent 
activation in mast cells and sheds light into the molecular mechanisms driving dysregulated 
IL-6. Our data underscores a role for constitutive STAT5 activation, achieved by both JAK2 
and ERK-mediated activities, and PI3K/AKT signals on IL-6 dysregulation. Together, our 
findings establish the groundwork for exploring new potential therapeutic combinations 




AKT, protein kinase B; BM, bone marrow; BMMCs, bone marrow-derived mast cells; 
C48/80, compound 48/80; C5a, complement component 5a; EGFR, epidermal growth factor 
receptor; ERK, extracellular signal–regulated kinase; HER, human epidermal growth factor 
receptor; HCT116, human colorectal carcinoma cell line; HMC-1, human mast cell line-1; 
IL-1β, interleukin-1 beta; IL-6, interleukin-6; JAK, janus kinase; KIT, receptor for stem cell 
factor; LAD2, laboratory of allergic diseases 2 cell line; LPS, lipopolysaccharide MAPK, 
mitogen-activated protein kinase;  MCBS-1, mast cell biology section-1 cell line; MEK1/2, 
mitogen-activated protein kinase kinase; MFI, mean fluorescence intensity; PI3K, 
phosphatidylinositide 3-kinase; PMA, phorbol 12-myristate 13-acetate; p38, p38 mitogen-
activated protein kinase; SCF, stem cell factor; sh-RNA, short hairpin ribonucleic acid; si-
RNA, small interfering ribonucleic acid; SM systemic mastocytosis; STAT, signal 
transducer and activator of transcription; S1P, sphingosine-1-phosphate; TGFβ, transforming 
growth factor β. 
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Figure legends  
 
Figure 1. Production of IL-6 by bone marrow cells and mast cells is enhanced in 
patients with SM in association with the D816V-KIT allelic burden. (A) IL-6 release 
from BM mononuclear cells isolated from five patients with SM with D816V-KIT bone 
marrow allelic frequencies of <5 (patients 4 and 5 in Supplementary Table 1) or >5 (patients 
6, 7, and 10). BM aspirates were cultured for 2-4 days and IL-6 released into the culture 
media was measured by ELISA. Data are the mean ± SEM. (B) Correlation between IL-6 
released into the media by BM cells and the percentage of mast cells in those cultures which 
was determined by flow cytometry. (C) Flow cytometry histograms showing intracellular IL-
6 staining in BM mast cells. Mast cells were gated as CD3-/CD34-/KIT+/FcεRI+ within the 
BM cells of three patients (patients 1-3 in Supplementary Table 1), with D816V-KIT allelic 
frequencies in the bone marrow also indicated in the figure. Patient 1had idiopathic 
anaphylaxis and did not meet criteria for SM but was used as a control. The percentage of IL-
6 positive cells within the mast cell population is indicated in the histograms.  
 
 
Figure 2. Cells with D816V-KIT constitutively express and release IL-6. (A) IL-6 mRNA 
expression (left) and IL-6 released into the media (right) by the mastocytosis cell lines HMC-
1.1 (with V560G) and HMC-1.2 (with V560G and D816V) after 2 h in serum free media. (B-
C) Comparison of IL-6 released into the media by the mouse P815 mastocytoma mast cell 
line (with D814Y-KIT) compared to normal murine BMMCs (B), and by the murine mast 
cell line MCBS-1 (which lacks c-Kit) transfected with human KIT or D816V-KIT compared 
to MCBS-1 transfected with vector alone (C). (D) Comparison of IL-6 mRNA expression 
(left) and IL-6 released into the media (right) by the human colorectal carcinoma cell line 
HCT116 expressing or not D816V-KIT. HCT116 cells were stimulated with PMA and 
ionomycin overnight. IL-6 mRNA expression was determined by q-RT-PCR and relative 
expression was calculated in relationship to the expression of GAPDH using the ΔCt method 
and expressed as fold change compared to HMC-1.1 (A, left panel), or the HCT116 parental 
cell line (D, left panel). All data (A-D) are the mean ± SEM of three independent experiments 
done in triplicates.  
 
Figure 3. D816V-KIT oncogenic activity drives ligand-independent IL-6 induction. (A) 
IL-6 released to the extracellular media was measured in LAD2, HMC-1.1 and HMC-1.2 
cells incubated for 48 h (37C, 5%CO2) in serum free medium in the presence or absence of 
100 ng/mL SCF. (B) IL-6 mRNA levels were measured in HMC-1.2 after 2 h incubation in 
serum free medium in the presence or absence of the KIT inhibitors, dasatinib and imatinib, 
or the EGFR inhibitor gefitinib at the indicated concentrations. Relative expression of IL-6 
mRNA was obtained by normalizing to the expression of GAPDH using the ΔCt method and 
the results are expressed as fold change compared to untreated cells. The effect of the KIT 
inhibitor dasatinib (0.5 µM) on the secretion of IL-6 by HMC-1.2 (C) or by P815 mast cells 
(D) was determined after 6 h incubation in serum free medium. All data are the mean ± SEM 
of three independent experiments done in triplicates.  
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Figure 4. MEK/ERK-, PI3K- and JAK2-mediated pathways are independently 
activated by D816V-KIT and contribute to ligand-independent IL-6 induction. (A-B) 
Effect of inhibition of MEK/ERK1/2 (U0126), p38 (SB203580) (A) or PI3K pathways 
(LY294002) (B) on the expression of IL-6 mRNA (left panels) after treatment for 2 h and the 
release of IL-6 into the media (right panels) by HMC-1.2 cells for 16 h. (C) Effect of the 
JAK2 inhibitor fedratinib at the indicated concentrations on the expression of IL-6 mRNA 
(left) and the release of IL-6 into the media (right) by HMC-1.2 cells. (D) Effect of various 
concentrations of inhibitors for JAK1/2 (ruxolitinib) and JAK3 (tofacitinib) on the expression 
of IL-6 mRNA by HMC-1.2 cells. E) Effect of inhibition of MEK/ERK1/2, PI3K or JAK2 on 
the production of IL-6 by mouse P815 cells after 6 h of incubation. (F) Effect of inhibitors 
for KIT (KIT-I: dasatinib; 0.5 µM), JAK2 (JAK2-I: fedratinib; 1 µM), PI3K (PI3K-I: 
LY294002; 10 µM) and MEK/ERK1/2 (ERK-I: U0126; 10 µM) on the phosphorylation of 
KIT, JAK2, AKT and ERK1/2 in the indicated amino acid residues. In F, inhibitors were 
incubated for 2 h in serum free medium. Numbers under each phosphorylated band are mean 
± SEM of at least three experiments and represent fold changes in the relative band 
fluorescence (normalized to the corresponding total expression) compared to untreated cells. 
Relative expression of IL-6 mRNA was obtained by comparing to the expression of GAPDH 
using the ΔCt method and the results were expressed as fold change compared to untreated 
cells. Data represent the mean ± SEM and are from three independent experiments. 
 
Figure 5. STAT5A and B are key in mediating D816V-KIT-induced persistent IL-6 
production. Effect of STAT3 (A) and STAT4 (B) knockdown by lentiviral sh-RNA on their 
respective targets and on the expression of IL-6 mRNA by HMC-1.2 cells. For sh-STAT4, 
the effect of two different constructs are shown (#1 and #3). Western blot gels underneath the 
bar graphs represent the effect of sh-STAT3 (A) or sh-STAT4 (B) constructs on the protein 
levels of STAT3 and STAT4, respectively. Lysates from duplicate samples are shown. The 
numbers under each pair are mean ± SEM of at least 3 separate experiments and represent 
fold change in the relative band fluorescence compared to the sh-RNA non-target (control). 
Actin content was used as loading control. (C, D) Effect of silencing STAT5A, STAT5B or 
the combination of both STAT5A&B by si-RNA on the expression of STAT5A and STAT5B 
mRNA (C) and of IL-6 mRNA (D) in HMC-1.2. The blots under the bar graph in C show the 
effect of STAT5 silencing in the protein levels of STAT5A/B and the numbers under the 
blot, the fold change as in A and B. Of note, the antibody used recognizes both STAT5A and 
B.  
 
Figure 6. MEK/ERK signaling pathway cooperates with JAK2 in the regulation of 
STAT5 to induce IL-6 while PI3K regulates IL-6 independently of STAT5. (A) Effect of 
inhibitors for KIT (KIT-I: dasatinib; 0.5 µM), JAK2 (JAK2-I: fedratinib; 1 µM), PI3K 
(PI3K-I: LY294002; 10 µM) MEK/ERK1/2 (ERK-I: U0126; 10 µM), STAT5 (STAT5-I: 
CAS285986-31-4; 50 µM), or their combination on the protein and phosphorylation levels of 
STAT5 in HMC-1.2 cells. (B) Effect of inhibitors of JAK2 and ERK1/2 alone or in 
combination on STAT5 phosphorylation in HMC-1.2 cells. In A and B, lysates were obtained 
after 2 h incubation with the indicated inhibitors in serum free medium. Data under the blots 
are the mean ± SEM of three independent experiments done in duplicates and represent fold 
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change in the relative band fluorescence compared to the untreated. STAT5 content was used 
to normalize the data. (C) Inhibition of MEK/ERK1/2 reduces STAT5A and STAT5B 
expression (upper and lower panels, respectively) after 16 h incubation. Relative expression 
of STAT5 mRNA was obtained by comparing to the expression of GAPDH using the ΔCt 
method and the results are expressed as fold change compared to untreated cells at each time 
(2 h or 16 h). (D, E) Inhibitors for STAT5, PI3K and MEK/ERK1/2 additively prevent IL-6 
mRNA induction (D, left panel) and IL-6 release in HMC-1.2 cells (D, right panel) and P815 
cells (E). The release of IL-6 into the media was determined after 6 h. (F) Inhibitors for 
JAK2, PI3K and MEK/ERK1/2 additively prevent IL-6 mRNA induction in HMC-1.2 cells. 







 Tobío et al., 1 
Supplementary Appendix 
 
Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 
production 
 
Araceli Tobío1, Geethani Bandara1, Denise A. Morris1, Do-Kyun Kim1, Michael P. 
O’Connell2, Hirsh D. Komarow1, Melody C. Carter1, Daniel Smrz1, Dean D. Metcalfe1 ¶, 
Ana Olivera1¶* 
 
1Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy 
and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA 
 
2Genetics and Pathogenesis of Allergy Section, Laboratory of Allergic Diseases, National 
















Supplementary Table 1 
Supplementary Table 2 
Supplementary Figures S1-S5 
Supplementary References 
  





Inhibitors and antibodies 
 
Anti-IL-6R tocilizumab (Actemra®) was obtained from Genentech (CA, SA). The PI3K 
inhibitor LY294002, was from Calbiochem EMD Millipore (CA, USA). Inhibitors of 
MAPK, (U0216), JAK (ruxolitinib phosphate), p38 (SB203580) and EGFR (gefitinib) 
were purchased from MCE MedChem Express (NJ, USA). The JAK2 inhibitor fedratinib 
(TG101348) and JAK3 inhibitor tofacitinib were from Selleckchem (TX, USA). Inhibitors 
of STAT3 (C188-9) and STAT5 (CAS285986-31-4), and the anti-b-actin antibody were 
from Millipore Sigma (MI, USA). Anti-pKIT(Y823), anti-JAK2, anti-ERK, anti-STAT4, 
anti-STAT5, anti-pSTAT5(S780) anti-CD3-QDOT605 and Fc receptor binding inhibitor 
polyclonal antibody were from ThermoFisher Scientific (IL, USA). Anti-KIT was from 
Santa Cruz Biotechnology (TX, USA). Anti-CD34-APC was from BD (CA, USA). Anti-
KIT-BV421 and anti-FcɛRI-FITC were from BioLegend (CA, USA). Anti-
pJAK2(Y1007/1008), anti-AKT, anti-pAKT(Y308), anti-pERK(Y202/204), anti-STAT3, 
anti-pSTAT3(Y705), anti-pSTAT4(Y693) and anti-pSTAT5(Y694) were from Cell 
Signaling. Anti-gp130 was from R&D Systems (MN, USA). Antagonists for the S1P 
receptors S1P1 and S1P3 (VPC 23019), S1P2 (JTE 013), and S1P4 (CYM 50358) and the 
TGFβR antagonist SD208 were form Tocris (UK).  
 
Cell cultures and cell lysates 
 
The human mast cell lines HMC-1.1 and HMC-1.2 were kindly provided by Dr. JH 
Butterfield (Mayo Clinic, Rochester, MN, USA)1 and cultured as described.2 HMC-1.1 
carries a variant in the juxta membrane domain of KIT (V560G) and HMC-1.2 harbors 
KIT with D816V plus the V560G variant 3. An immortalized murine mast cell line that 
does not express mouse KIT, MCBS-1, was stably transfected with human WT and 
D816V-KIT and cultured as described.4 The murine mastocytoma cell line P815 was from 
ATCC and cultured as specified by the provider. BM-derived mast cells (BMMCs) from 
C57BL/6 mice were cultured as described 5. The human colorectal carcinoma cell lines 
HCT116 modified or not by CRISPR to introduce a D816V-KIT mutation, were purchased 
from ThermoFisher Scientific (CA, USA) and cultured in RPMI with 10% FBS, 2 mM L-
Glutamine and 25 mM Sodium Bicarbonate. LAD2 human MCs were cultured in StemPro-
34 Complete Medium (Invitrogen, NY, USA) with SCF (100 ng/mL) (R&D Systems, MN, 
USA), as described.6 
 
To obtain lysates for western blots, 3x106 cells were plated in 6 well plates and incubated 
with the indicated inhibitors for 2 h in serum-free media. Cells were then washed with PBS 
and lysed in lysis buffer [150 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 1 mM 
Na3VO4, 0.5 mM PMSF, 5 mg/ml aprotinin, 5 mg/ml leupeptin, complete protease inhibitor 
cocktail (Roche, Indianapolis, IN) and 1% NP-40] for 15 min as described.7 
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Stimulation of LAD2 cells by HMC-1.2 conditioned media 
 
HMC1.2 conditioned media (serum-free) from overnight cultures under the conditions 
described below were collected after centrifugation at 1100 x rpm for 5 min and added to 
2x106 LAD2 cells plated in 6 well plates. LAD2 cells were previously starved in cytokine 
free media for 4 h at 37oC. HMC-1.2 conditioned media (5 mL) were added to LAD2 cells 
for 30 min in the presence or absence of the neutralizing IL-6R antibody tocilizumab (100 
µg/mL).  Tocilizumab was added during the final 20 minutes during the starvation period 
as well as during the incubation with conditioned media. Recombinant IL-6 (50 ng/mL) 
was used as positive control. Plates were then transferred to ice for 2 min and cell pellets 
were obtained and washed once with cold PBS.  Cells were lysed on ice in 80 µL of lysis 
buffer (100 µM Tris, 150 mM NaCL, 1% triton-X100, a cocktail of protease inhibitor 
(cOmpleteTM ultra mini, EDTA free; Millipore-Sigma) and a cocktail of phosphatase 
inhibitors (Phosptop; Millipore-Sigma)). Protein content in clarified lysates was measured 
using Pierce BCA protein assay (Thermo Fisher) and 50 µg of proteins were loaded on to 
SDS PAGE gels. STAT3 and pSTAT3-Y705 contents were determined by Western 
blotting to evaluate IL-6R activation. 
 
Measurement of IL-6 secreted into the media  
 
HMC-1, BMMCs, P815, HCT116 or MCBS-1 cells (3x106), were plated in 6 well plates 
for 2 h to 24 h in 6 mL of serum-free media, as indicated in the figure legends. The 
experiments were performed in the absence of FBS to exclude the possibility that any 
extrinsic stimulant present in the serum would influence results. Aliquots of the supernatant 
were kept at -80oC and the amounts of IL-6 measured by ELISA (R&D Systems). HCT116 
cells were stimulated with 20 ng/mL PMA plus 1 µM ionomycin overnight and the 
supernatants then collected for IL-6 measurements. In some experiments, we determined 
the fraction of released IL-6 versus the amount remaining in cells in the presence or absence 
of various stimulants.  HMC-1.2 cells (3 x 106) were cultured overnight in serum-free 
media containing a protease inhibitor cocktail (cOmpleteTM ultra mini, EDTA free; 
Millipore-Sigma) alone or in combination with one of the following stimuli: the 
secretagogue compound 48/80 (C48/80) (500 ng/mL); complement component 5a (C5a) 
(500 ng/mL); PMA (20 ng/mL) and Ionomycin (1 µM); lipopolysaccharide (LPS) (10 
µg/mL); IL-1b (100 ng/mL); or media containing 10% FBS. Cells were centrifuged at 1100 
rpm for 5 min and IL-6 in the supernatants measured by ELISA.  Cell pellets were washed 
and resuspended in 500 µL of cold PBS containing the protease inhibitor cocktail, freeze-
thawed 5 times and clarified by centrifugation at 14,000 rpm.  IL-6 amounts in the resulting 
supernatants (intracellular IL-6) were also determined by ELISA.  
 
 For measurement of IL-6 released by human BM cells, mononuclear cells from BM 
aspirates from subjects described in Supplementary Table 1 were cultured in StemPro-34 
medium with human recombinant SCF (100 ng/mL) and supernatants collected after 2-4 
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days. In some experiments, the number of mast cells present in these cultures was 
determined by flow cytometry as indicated below.  
 
Determination of single-cell IL-6 expression in cultures from bone marrow aspirates  
 
Mononuclear cells from the BM aspirates were cultured (1x106/mL) as described above for 
2-4 days. BM cells were then incubated with Brefeldin A for 4 h (37oC) and washed with 
PBS+1% BSA. Fc receptors were blocked with Fc blocking antibody (1:100) for 8 min and 
cells were stained with 100 μL of an antibody cocktail containing anti-CD3-QDOT605, 
anti-CD34-APC, anti-KIT-BV605 and anti-FcεRI-FITC, for 30 min at room temperature. 
Cells were then fixed with 4% paraformaldehyde for 8 min at room temperature and 
permeabilized with 150 µL of BD Perm/Wash buffer (BD). Expression of IL-6 was 
detected by staining the cells with anti-IL-6-PE for 30 min, using a LSRII flow cytometer 
(BD Biosciences, Sparks, MD) and analyzed using FlowJo software (Tree Star, Ashland, 
OR). CD3-/CD34-/KIT+/FcεRI+ (mast cells) were gated, and IL-6 positive cells analyzed 
using FlowJo software (Tree Star, Ashland, OR). 
 
Immunofluorescence staining of intracellular IL-6 in bone marrow specimens 
 
Bone marrow trephine biopsies were fixed in B‐5 fixative, decalcified in EDTA and 
embedded in paraffin using standard procedures.  Sections were deparaffinized in xylene 
and rehydrated using an alcohol gradient. Following washes in water and PBS, samples 
were steamed for 20 minutes in antigen retrieval solution (Tris-HCl/EDTA; pH 9.0 (Vector 
Labs, Burlingame, CA, USA)). After washing with PBS, slides were blocked with 
immunofluorescent blocking buffer (0.2% Triton X-100, 0.2% BSA, 0.2% casein, 0.2% 
gelatin, and 0.02% sodium azide) containing 5% donkey serum.  Slides were then probed 
with anti‐mast cell tryptase (10 µg/mL; Abcam# ab2378) and anti-IL-6 (5 µg/mL; Abcam# 
ab214429) antibodies in immunofluorescent blocking buffer containing 1% donkey serum 
and incubated at 4oC overnight. Slides were washed 3x in PBS and probed with the 
appropriate secondary antibodies (donkey anti-rabbit Alexa-488 and donkey anti-mouse 
Alexa-568, Molecular Probes, Thermo, Rockville, MD, USA) in immunofluorescent 
blocking buffer containing 1% donkey serum for 1 h at room temperature. Next, samples 
were washed 3x in PBS and stained using DAPI/PBS (1 µg/mL) for 20 minutes at room 
temperature, washed 3x PBS, and mounted in PermaFluor mounting medium (Thermo 
Scientific). Samples were visualized using a Zeiss 710 Meta confocal microscope using a 
40x oil objective. Laser settings for the capture of images and adjustments of levels and 
brightness were identical among specimens.  Imaging software used for visualization was 
Zeiss Zen (Carl Zeiss Microscopy, Thornwood, NY, USA) and Adobe Illustrator (Adobe 
Systems, San Jose, CA, USA). 
 
Quantitative real-time PCR 
 
HMC-1.2 cells (3x106) were plated in 6-well plates in 6 mL and incubated for 2 h in serum 
free media. RNA was then isolated from cells with RNeasy Plus Mini Kit (Qiagen, KY, 
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USA) following the manufacturer’s protocol and cDNA was synthetized by reverse 
transcription using the SuperScript III First-Strand kit (Thermo Fisher Scientific, CA, 
USA) with random hexamers. The corresponding cDNA was amplified in a CFX96 
TouchTM Real-Time detection system (Biorad®), using TaqMan® Gene Expression Master 
Mix and Taqman® Gene Expression Assays for IL-6 (Hs00985639_m1), STAT3 
(Hs01047580_m1), STAT4 (Hs01028017_m1), STAT5A (Hs00559637_g1), STAT5B 
(Hs00560026_m1) or GAPDH (Hs99999905_m1) following the manufacturer's standard 
protocol (Thermo Fisher Scientific, CA, USA). Analysis of the data was performed using 
CFX Maestro Software and relative expression was calculated with the ∆Ct method with 
GAPDH as the housekeeping gene.  
 
Knockdown of STAT3 and STAT4 transcription factors by sh-RNA  
 
Bacterial glycerol stocks expressing lentivirus plasmids (MISSION-pLKO-1-puro) with 
inserts of small hairpin RNA (sh-RNA) were purchased from Sigma-Aldrich (Sigma-
Aldrich, St. Louis, MO). The lentiviral pLKO-1-puro plasmids contained sh-RNA 
sequences specific for STAT3 (TRCN0000020840), STAT4 (TRCN0000020894: 
construct #1; and TRCN0000020895: construct #3), STAT5A (TRCN0000019304, 
TRCN000019306 and TRCN0000019308), STAT5B (TRCN0000232141, 
TRCN0000232140 and TRCN0000232137), or non-target control vector (SHC002). These 
plasmids were isolated from the corresponding bacteria cultures using QIAprep Spin 
Miniprep Kit (Qiagen). To produce the lentiviral particles, HEK 293T (4x106 cells) were 
co-transfected with the corresponding purified lentiviral vectors (3.4 μg) and plasmids 
coding for key packaging and structural viral proteins (lentiviral packaging mix from 
Sigma-Aldrich) (34 µL) using the FuGENE6 transfection reagent (21 μL) (Roche, 
Indianapolis, IN) in 236 µL of RPMI. A day after transfection, the culture media was 
replaced with fresh media and collected 24 h later, when most of the viral production takes 
place. The media containing the viral particles was centrifuged at 2,000rpm for 10 min to 
eliminate cell remnants and then aliquoted and frozen at -80C until use.  
 
For sh-RNA knockdown, 0.3x106 HMC-1.2 cells were plated in 0.5 mL of media in 48-
well plates and the lentivirus preparations (250 µl) were added. All lentiviral preparations 
were tittered for their effects on the gene target and 250 µL was usually within the optimal 
range. Two days after transduction, cells were washed, incubated for 2 h in serum-free 
media and tested for IL-6 expression. Of note, all lentiviral plasmids caused substantial 
reductions in the intended targets, except for the three constructs tested for each STAT5A 
and STAT5B which all proved ineffective in these cells. 
 
Knockdown of STAT5 transcription factor by si-RNA  
 
To knockdown STAT5 by small interference-RNA (si-RNA), the si-RNA constructs were 
introduced into the cells by electroporation using a nucleofector 2b device from Lonza 
(Cologne, Germany) (program T-020). HMC-1.2 cells (2x106) were washed with PBS and 
resuspended in 100 μL of nucleofector Kit V solution (Lonza) containing 2 μM of a si-
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RNA “ON-TARGET” pool for human STAT5A (L-005169-00-0005), STAT5B (L-
010539-00-0005), or a non-targeting si-RNA pool (D-001810-10-05) from Dharmacon 
(Lafayette, CO). Transfected cells were kept in culture at 37oC in 5% CO2 for 72 h. Cells 
were then washed, incubated in serum free culture media for 2 h and their cellular protein 
or RNA contents extracted.  
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Supplementary Table 1- D816V-KIT allelic frequency and tryptase levels in the 
patients used in this study  
 
Patient 





1 IA* F Negative   4 
2 ISM M  2.74  35 
3 ISM M  5.50 182 
4 ASM F  1.41 479 
5 ISM F  0.35 105 
6 ISM F 31.08 293 
7 ISM M 13.44 291 
8 ISM M    0.06  14 
9 ISM M    0.03  10 
10 SSM M 44.66 590 
 
 
*BM aspirates were obtained from this patient with idiopathic anaphylaxis (IA) during an evaluation for 
possible SM. SM was not diagnosed in this patient and thus findings were used as a control in this study. 
ISM: indolent systemic mastocytosis; SSM: smouldering systemic mastocytosis. Patients were classified 
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1/ (0.0%) - 21 - 17 - 20 - 17 
2/ (2.7%) 336 74 167 56 254 61 117        47 
3/ (5.5%) 3371 98 768 88 524 86   522 73 
 
 
BM cells were cultured for 3-4 d and intracellular IL-6 staining in Brefeldin A- treated cells was analyzed by 
FACS. CD3-/CD34- cells were gated and the mean fluorescence intensity (MFI) of intracellular IL-6 and the 
percentage of cells with IL-6+ staining determined within each population (KIT+/FcεRI+, KIT+/FcεRI-, KIT-
/FcεRI+ and KIT-/FcεRI-).  Patients 1-3 are the same as shown in Figure 1C and as defined in Supplementary 
Table 1. Patient 1 had idiopathic anaphylaxis and did not meet criteria for SM but was used as a control.  
 
  







Supplementary Figure S1. Intracellular IL-6 in bone marrow specimens from 
patients with SM is mainly associated with mast cells.  Bone marrow biopsies from 
patients # 7 (A) and #10 (C) defined in Supplementary Table 1 were prepared for 
immunofluorescence staining with anti-mast cell tryptase (red) and anti-IL-6 (green). 
Nuclei were identified by DAPI staining. In the overlay, proximal co-localization is shown 
in yellow or white depending on the intensity of the individual anti-tryptase and anti-IL-6 
staining. Shown are areas with disperse mast cell infiltration for better visualization. Scale 
bars are 50 µM (left panels) and 20 µM (right panels).  Right panels are the magnified areas 












































Supplementary Figure S2- Autocrine activation of IL-6, S1P and TGF-β receptors 
does not mediate the constitutive expression of IL-6 in HMC-1.2 cells. Effect of anti-
IL-6 receptor (IL-6R) antibody (tocilizumab; 100 µg/mL) (A, left panel), anti-gp130 
antibody (1 µg/mL) (A, right panel), S1PR1,3, S1PR2 and S1PR4 antagonists (VPC 23019; 
1 µM, JTE 013; 1 µM and CYM 50358; 1 µM) (B) and a TGFβ-R antagonist (SD 208; 5 
µM) (C), on IL-6 secretion by HMC-1.2 cells. The antibodies and antagonists were 
incubated for 24 h in serum free media. The data represent mean ± SEM of two experiments 



































Supplementary Figure S3. Constitutive secretion of IL-6 by HMC-1.2 is enhanced by 
various stimuli; and secreted IL-6 is biologically active. (A) Total IL-6 released into the 
media by HMC-1.2 in comparison with total intracellular IL-6. Cells were incubated at 
37oC overnight in serum free media with or without C48/80 (500 ng/mL), C5a (500 
ng/mL), PMA (20 ng/mL) and Ionomycin (Io) (1 µM), LPS (10 µg/mL), IL-1b (100 
ng/mL), or full media containing 10% FBS. In the right panel, the effects of the KIT 
inhibitor dasatinib (0.5 µM) on released IL-6 and intracellular IL-6 are shown. The 
percentages of intracellular compared to released IL-6 were 10% with or without dasatinib, 
or in the presence of C48/80; 6% after stimulation with C5a, LPS and PMA/Io; and 2% 
after incubation with IL-1b or 10% FBS. (B) IL-6 released by HMC-1.2 induces STAT3 
phosphorylation in LAD2 cells. LAD2 cultures were treated for 30 min with conditioned 
media from HMC-1.2 (HMC-1.2-C.M.) in the presence or absence of the neutralizing IL-
6R antibody tocilizumab (100 µg/mL) or incubated with serum-free media with or without 
50 ng/mL recombinant IL-6. Cell lysates were obtained and phosphorylation of STAT3 
determined by Western blotting. 







Supplementary Figure S4. Baseline expression levels and phosphorylation state of 
STAT family members in HMC-1.2 compared to HMC-1.1 cells. (A) Expression levels 
of STAT3 mRNA (upper panel) and protein (lower panel) in HMC-1.1 and HMC-1.2 cells. 
(B) Expression levels of STAT4 mRNA (upper panel) and protein (lower panel) in HMC-
1.1 and HMC-1.2 cells. (C) Expression levels of STAT5 mRNA (left panel, STAT5A; 
middle panel, STAT5B) and protein (right panel) in HMC-1.1 and HMC-1.2 cells. Both 
phosphorylated and total STAT family members are shown. Relative expression of STAT 
mRNA was obtained by comparing to the expression of GAPDH using the DCt method and 
the results were expressed as fold change compared to HMC-1.1 cells. Cells were incubated 
for 2 h in serum-free media before obtaining the cell lysates or RNA. The data represent 
mean ± SEM of three experiments performed in duplicate. 
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Supplementary Figure S5. Inhibition of STAT5 but not STAT3 reduces constitutive 
expression of IL-6 by HMC-1.2 cells. (A) Effect of the small STAT3 inhibitor, C188-9, 
at the indicated concentrations, on STAT3 phosphorylation (upper panel) and the 
expression of IL-6 mRNA (lower panel). (B-C) Effect of the STAT5 inhibitor CAS285986-
31-4, at the indicated concentrations, on STAT5 phosphorylation (B, upper panel), the 
expression of IL-6 mRNA (B, lower panel) and IL-6 protein (C) in HMC-1.2 cells. The 
expression of IL-6 protein in C was evaluated by intracellular staining and FACS analysis 
as described in Methods. (D) Effect of the STAT5 inhibitor on IL-6 secretion by P815 cells. 
In A-D, cells were incubated in serum-free media with the corresponding inhibitors for 2 h 
(IL-6 mRNA expression) or 6 h (IL-6 release). (E) Combined effect of knocking down both 
STAT5A and B by si-RNA and incubation with the STAT5 inhibitor for 2 h, at the 
indicated concentrations, on the constitutive expression of IL-6 in HMC-1.2. Relative 
expression of IL-6 mRNA was obtained by comparing to the expression of GAPDH using 
the DCt method and the results were expressed as fold change compared to untreated or 
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